Candriam SCA’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Candriam SCA’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,377	Closed	-$450K	–	894
2023 Q1	$450K	Buy	+5,377	New	+$316K	﹤0.01%	789
2021 Q2	–	Sell	-151,707	Closed	-$18M	–	945
2021 Q1	$18M	Hold	151,707	–	–	0.15%	151
2020 Q4	$18.8M	Sell	151,707 -4,877	-3%	-$641K	0.15%	152
2020 Q3	$15.3M	Hold	156,584	–	–	0.14%	166
2020 Q2	$24.4M	Buy	156,584 +41,184	+36%	+$6.26M	0.26%	101
2020 Q1	$23.1M	Hold	115,400	–	–	0.26%	80
2019 Q4	$23.6M	Sell	115,400 -80,800	-41%	-$14.7M	0.25%	80
2019 Q3	$15.8M	Sell	196,200 -53,000	-21%	-$4.5M	0.21%	110
2019 Q2	$23.4M	Hold	249,200	–	–	0.29%	74
2019 Q1	$21.3M	Buy	249,200 +50,000	+25%	+$4.15M	0.27%	83
2018 Q4	$11.2M	Buy	199,200 +4,000	+2%	+$244K	0.17%	137
2018 Q3	$16M	Buy	195,200 +48,500	+33%	+$3.42M	0.21%	112
2018 Q2	$5.13M	Buy	146,700 +54,700	+59%	+$1.67M	0.08%	294
2018 Q1	$1.89M	Hold	92,000	–	–	0.03%	492
2017 Q4	$2.6M	Buy	92,000 +32,000	+53%	+$893K	0.05%	402
2017 Q3	$1.87M	Buy	+60,000	New	+$1.8M	0.03%	468

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA's RETA Position: Q2 2023 in Review

Candriam SCA sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 5,377 shares — an estimated $450K sold.

Candriam SCA first reported a position in RETA in Q3 2017 and held it in 16 quarters. The position peaked at $24.4M in Q2 2020. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Candriam SCA reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 5,377 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $450K.
Candriam SCA first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 16 quarters.
Candriam SCA's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $24.4M in Q2 2020.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.